IQVIA Holdings Inc. Files 2023 Annual Report on Form 10-K

TL;DR

<b>IQVIA Holdings Inc. has filed its 2023 annual report (10-K) detailing its financial performance and business operations for the fiscal year ending December 31, 2023.</b>

AI Summary

IQVIA HOLDINGS INC. (IQV) filed a Annual Report (10-K) with the SEC on February 15, 2024. IQVIA Holdings Inc. filed its 2023 Form 10-K on February 15, 2024. The report covers the fiscal year ending December 31, 2023. The company's principal executive offices are located at 2400 Ellis Road, Durham, NC 27703. IQVIA was formerly known as Quintiles IMS Holdings, Inc. and Quintiles Transnational Holdings Inc. The filing includes financial data for the fiscal years 2021, 2022, and 2023.

Why It Matters

For investors and stakeholders tracking IQVIA HOLDINGS INC., this filing contains several important signals. This 10-K filing provides a comprehensive overview of IQVIA's financial health, operational performance, and strategic direction for the past fiscal year, which is crucial for investors to assess the company's value and future prospects. Understanding the details within this filing allows stakeholders to evaluate IQVIA's compliance with regulatory requirements and its position within the commercial and biological research services industry.

Risk Assessment

Risk Level: medium — IQVIA HOLDINGS INC. shows moderate risk based on this filing. The company's business is subject to various risks and uncertainties inherent in the life sciences and healthcare industries, including regulatory changes and competitive pressures, as detailed in the full 10-K filing.

Analyst Insight

Investors should review the detailed financial statements and risk factors in the 10-K to understand IQVIA's performance and potential challenges.

Key Numbers

• 2023-12-31 — Fiscal Year End (Period of report)
• 2024-02-15 — Filing Date (Date filed)
• 271341991 — IRS Number (Company's IRS number)
• 001-35907 — SEC File Number (Company's SEC file number)

Key Players & Entities

• IQVIA HOLDINGS INC. (company) — Filer name
• 2023-12-31 (date) — Fiscal year end
• 2024-02-15 (date) — Filing date
• 2400 ELLIS ROAD (address) — Business address street 1
• DURHAM (address) — Business address city
• NC (address) — Business address state
• 27703 (address) — Business address zip
• Quintiles IMS Holdings, Inc. (company) — Former company name

FAQ

Industry Context

IQVIA operates in the commercial and biological research services sector, providing advanced analytics, technology solutions, and clinical research services to the healthcare industry.

Regulatory Implications

As a publicly traded company, IQVIA is subject to the reporting requirements of the Securities and Exchange Commission (SEC), including the annual filing of Form 10-K.

What Investors Should Do

1. Review IQVIA's detailed financial statements for the fiscal year 2023.
2. Analyze the risk factors section for potential business challenges and mitigation strategies.
3. Compare IQVIA's 2023 performance against previous years and industry benchmarks.

Key Dates

• 2023-12-31: Fiscal Year End — The end date of the reporting period for the 10-K filing.
• 2024-02-15: Filing Date — The date the 10-K report was officially submitted to the SEC.

Year-Over-Year Comparison

This filing represents the annual 10-K for the fiscal year ending December 31, 2023, providing updated financial and operational information compared to previous filings.

Key Financial Figures

• $0.01 — ich registered Common Stock, par value $0.01 per share IQV New York Stock Exchange
• $330 billion — We compete in a market of greater than $330 billion consisting of outsourced research and d
• $184 billion — drug development totaled approximately $184 billion in 2023. Of that amount, we estimate th
• $99 billion — preclinical spending) was approximately $99 billion. The portion of this addressable opport
• $50 billion — sed on our estimates, was approximately $50 billion. Real-World Evidence and connected he
• $70 billion — tal addressable market of approximately $70 billion in 2023 that consists of tightly couple
• $30 billion — or Real-World Evidence of approximately $30 billion includes post-launch evidence generatio
• $40 b — r connected healthcare is approximately $40 billion, and includes areas such as reven
• $80 billion — tal addressable market of approximately $80 billion in 2023 that includes information, data
• $1.63 — timated to have generated approximately $1.63 trillion in revenues in 2023. According

Filing Documents

• iqv-20231231.htm (10-K) — 3152KB
• ex-41descriptionofthecompa.htm (EX-4.1) — 30KB
• ex-109formofconfidentialit.htm (EX-10.9) — 92KB
• ex-1010workproductassignme.htm (EX-10.10) — 45KB
• ex-1019imshealthincorporat.htm (EX-10.19) — 633KB
• ex-1027iqviasavingsequaliz.htm (EX-10.27) — 31KB
• ex-1028iqviaelectivedeferr.htm (EX-10.28) — 66KB
• ex-1029iqviaholdingsincnon.htm (EX-10.29) — 53KB
• ex-1035letteragreementbetw.htm (EX-10.35) — 113KB
• ex-21112312023.htm (EX-21.1) — 221KB
• ex-2314q2023consentdraft.htm (EX-23.1) — 2KB
• ex-3111231202310xk.htm (EX-31.1) — 9KB
• ex-3121231202310xk.htm (EX-31.2) — 9KB
• ex-3211231202310xk.htm (EX-32.1) — 6KB
• ex-3221231202310xk.htm (EX-32.2) — 6KB
• ex-971restatementrecoveryp.htm (EX-97.1) — 20KB
• image_0a.jpg (GRAPHIC) — 18KB
• image_1a.jpg (GRAPHIC) — 8KB
• iqv-20231231_g1.jpg (GRAPHIC) — 4KB
• iqv-20231231_g2.jpg (GRAPHIC) — 172KB
• 0001478242-24-000038.txt (&nbsp;) — 19695KB
• iqv-20231231.xsd (EX-101.SCH) — 117KB
• iqv-20231231_cal.xml (EX-101.CAL) — 149KB
• iqv-20231231_def.xml (EX-101.DEF) — 663KB
• iqv-20231231_lab.xml (EX-101.LAB) — 1386KB
• iqv-20231231_pre.xml (EX-101.PRE) — 1038KB
• iqv-20231231_htm.xml (XML) — 3250KB

FORWARD-LOOKING STATEMENTS

FORWARD-LOOKING STATEMENTS Except for any historical information contained herein, the matters discussed or incorporated by reference in this Annual Report on Form 10-K contains forward-looking statements within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended ("Securities Act"), and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). Such forward-looking statements reflect, among other things, our current expectations, our forecasts and our anticipated results of operations, all of which are subject to known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements, market trends, or industry results to differ materially from those expressed or implied by such forward-looking statements. Therefore, any statements contained herein that are not statements of historical fact may be forward-looking statements and should be evaluated as such. Without limiting the foregoing, the words "assumes," "anticipates," "believes," "estimates," "expects," "intends," "may," "forecasts," "plans," "projects," "should," "seeks," "sees," "targets," "will," "would" and similar words and expressions, and variations and negatives of these words are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. We caution you that any such forward-looking statements are further qualified by important factors that could cause our actual operating results to differ materially from those in the forward-looking statements, including without limitation, that business disruptions caused by natural disasters, pandemics such as the COVID-19 (coronavirus) outbreak, including any variants, and the public health policy responses to the outbreak, international conflict or other disruptions outside of our control such as the current situation in Ukraine and Russia; most of our contracts may

Business

Item 1. Business Our Company IQVIA is a leading global provider of advanced analytics, technology solutions, and clinical research services to the life sciences industry. IQVIA creates intelligent connections across all aspects of healthcare through its analytics, transformative technology, big data resources, extensive domain expertise and network of partners. IQVIA Connected Intelligence delivers actionable insights and powerful solutions with speed and agility — enabling customers to accelerate the clinical development and commercialization of innovative medical treatments that improve healthcare outcomes for patients. With approximately 87,000 employees, we conduct operations in more than 100 countries. We are a global leader in protecting individual patient privacy. We use a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. Our insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. We have one of the largest and most comprehensive collections of healthcare information in the world, which includes more than 1.2 billion comprehensive, longitudinal, non-identified patient records spanning sales, prescription and promotional data, medical claims, electronic medical records, genomics, and social media. Our scaled and growing information set contains approximately 61 petabytes of unique proprietary data sourced from approximately 150,000 data suppliers and covering over one million data feeds globally. Based on this data, we deliver information and insights on over 90

View Full Filing

View this 10-K filing on SEC EDGAR